Clinical Trial Update: Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab [Phase 1, Phase 2]

View source ↗

Summary

Results from a Phase 1/2 study evaluating ranibizumab at 0.5 mg and 2.0 mg for diabetic macular edema in patients with poor response to bevacizumab have been co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: California Retina Consultants | Conditions: Diabetic Macular Edema | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-04-22